Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Iron and vitamins may boost recovery in heart infection patients

NCT ID NCT07523646

Symptom relief Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding anemia treatment (iron, vitamins, and a hormone that boosts red blood cells) to standard care helps people with a serious heart valve infection feel better and walk farther. About 74 adults with both the infection and anemia will be enrolled. The goal is to see if this extra treatment improves strength and oxygen levels without causing harm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Confirmed bacterial endocarditis. * Hb ≤6.0 mmol/l * Stabilization criteria: * Stable condition (patients with satisfactory clinical response to initial treatment) * At least 10 days with IV administered antibiotic treatment and at least 7 days after surgery in cases of valve surgery. * Transesophageal echocardiography (TEE) performed prior to randomization with no signs of abscess formation or valve abnormalities, which would require surgery. * No fever for at least 48 hours prior to enrollment.No positive blood cultures within last 4 days prior to randomization. * CRP \< 25 mg/L OR \> 25% reduction from peak value. * Leucocytes \<15 mia./L OR \> 25% reduction from peak value. Exclusion Criteria: * Known or suspected immunocompromise (e.g., HIV infection, ongoing chemotherapy, systemic corti-costeroid treatment \>20 mg prednisolone equivalent/day) * Inability to provide informed consent for participation * Relapsing infective endocarditis (endocarditis caused by the same microorganism within 6 months) * Allergy / intolerance to EPO or iron therapy * Inability to complete a 6MWT * Hematological conditions, that contradicts use of IV iron therapy * Death prior to clinical stabilization * Failure to fulfill criteria of clinical stabilization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infective endocarditis (IE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia endocarditis infective endocarditis Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infective endocarditis (IE) Severe anemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Heart Centre, Department of Cardiology, Rigshospitalet - Copenhagen University Hospital

    RECRUITING

    Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.